- Home
- DTST vs CYTH Comparison
DTST vs CYTH Comparison
Compare DTST & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- CYTH
- Stock Information
- Founded
- DTST 2001
- CYTH 1990
- Country
- DTST United States
- CYTH United States
- Employees
- DTST N/A
- CYTH N/A
- Industry
- DTST EDP Services
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- DTST Technology
- CYTH Health Care
- Exchange
- DTST Nasdaq
- CYTH Nasdaq
- Market Cap
- DTST 32.7M
- CYTH 31.9M
- IPO Year
- DTST N/A
- CYTH N/A
- Fundamental
- Price
- DTST $3.47
- CYTH $0.70
- Analyst Decision
- DTST
- CYTH Buy
- Analyst Count
- DTST 0
- CYTH 3
- Target Price
- DTST N/A
- CYTH $0.95
- AVG Volume (30 Days)
- DTST 33.6K
- CYTH 101.2K
- Earning Date
- DTST 03-27-2025
- CYTH 03-21-2025
- Dividend Yield
- DTST N/A
- CYTH N/A
- EPS Growth
- DTST N/A
- CYTH N/A
- EPS
- DTST 0.02
- CYTH N/A
- Revenue
- DTST $25,143,911.00
- CYTH $870,725.00
- Revenue This Year
- DTST $2.57
- CYTH N/A
- Revenue Next Year
- DTST $11.16
- CYTH $24.49
- P/E Ratio
- DTST $172.37
- CYTH N/A
- Revenue Growth
- DTST 1.64
- CYTH N/A
- 52 Week Low
- DTST $3.24
- CYTH $0.55
- 52 Week High
- DTST $8.00
- CYTH $1.79
- Technical
- Relative Strength Index (RSI)
- DTST 36.06
- CYTH 42.28
- Support Level
- DTST $3.40
- CYTH $0.85
- Resistance Level
- DTST $3.64
- CYTH $0.80
- Average True Range (ATR)
- DTST 0.22
- CYTH 0.06
- MACD
- DTST -0.02
- CYTH -0.02
- Stochastic Oscillator
- DTST 15.63
- CYTH 15.93
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; Flagship Solutions, LLC and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.